BioSpace News Archive

Drug Development

Pfizer’s Weekly Injection Reduced Bleeding in Phase III Hemophilia Trial

Marstacimab decreased bleeding rates by 92% in patients with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors.

May 30, 2023
·
2 min read
·
Kate Goodwin
FDA

Lexicon Breaks Sotagliflozin Losing Streak with FDA Nod in Heart Failure

Following a series of stumbles in Type 1 diabetes, Lexicon’s dual SGLT inhibitor sotagliflozin finally won the FDA’s approval in heart failure and will be marketed as Inpefa.

May 30, 2023
·
3 min read
·
Tristan Manalac
Genetown

The Top Biotech Companies in Boston Hiring Now

Check out these hot Boston-based biotech companies hiring now.

May 30, 2023
·
2 min read
·
Rosemary Scott
Policy

European Regulator Leaning Toward Rejecting Amylyx’s ALS Drug

Known as Relyvrio in the U.S., Amylyx’s AMX0035 may face a longer road to approval in Europe as the company reported that CHMP could reject its marketing authorization application.

May 30, 2023
·
3 min read
·
Heather McKenzie
Drug Development

AstraZeneca Touts Positive Phase III Endometrial Cancer Data for Imfinzi, Lynparza

DUO-E trial data show AstraZeneca’s Imfinzi, either alone or in combination with Lynparza, boosts progression-free survival in endometrial cancer.

May 30, 2023
·
2 min read
·
Tristan Manalac
Drug Development

FDA Gives Akebia Glimmer of Hope for Rejected CKD-Related Anemia Drug

Akebia announced it will submit a new NDA targeting CKD patients on dialysis, which will not involve additional trials.

May 30, 2023
·
2 min read
·
Rosemary Scott
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

May 30, 2023
·
3 min read
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel

May 30, 2023
·
5 min read
Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy (“THT”) for colorectal cancer

May 30, 2023
·
4 min read
Nykode Therapeutics to Present at Jefferies 2023 Healthcare Conference

Nykode Therapeutics ASA announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the 2023 Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023, at 10:00 a.m. ET / 4:00 p.m. CET.

May 30, 2023
·
1 min read